Ubs Group Ag Larimar Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 19,874 shares of LRMR stock, worth $75,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,874

Previous 17,672 12.46%

Holding current value

$75,322

Previous $128,000 1.56%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $13,872 - $23,517	2,202 Added 12.46%	19,874 $130,000
Q2 2024 Aug 13, 2024	SELL	$6.33 - $9.89 $56,501 - $88,278	-8,926 Reduced 33.56%	17,672 $128,000
Q1 2024 May 13, 2024	SELL	$4.2 - $13.28 $6,052 - $19,136	-1,441 Reduced 5.14%	26,598 $201,000
Q4 2023 Feb 09, 2024	BUY	$2.35 - $4.71 $32,867 - $65,874	13,986 Added 99.52%	28,039 $127,000
Q3 2023 Nov 09, 2023	SELL	$3.08 - $4.49 $45,066 - $65,697	-14,632 Reduced 51.01%	14,053 $55,000
Q2 2023 Aug 11, 2023	BUY	$3.13 - $5.27 $71,185 - $119,855	22,743 Added 382.75%	28,685 $89,000
Q1 2023 May 12, 2023	BUY	$4.0 - $6.68 $23,480 - $39,211	5,870 Added 8152.78%	5,942 $26,000
Q4 2022 Feb 08, 2023	SELL	$2.73 - $5.08 $8,935 - $16,626	-3,273 Reduced 97.85%	72 $0
Q3 2022 Nov 10, 2022	BUY	$1.53 - $3.64 $4,198 - $9,988	2,744 Added 456.57%	3,345 $11,000
Q2 2022 Aug 10, 2022	SELL	$1.9 - $3.98 $2,150 - $4,505	-1,132 Reduced 65.32%	601 $1,000
Q1 2022 May 16, 2022	BUY	$3.65 - $10.84 $2,233 - $6,634	612 Added 54.59%	1,733 $7,000
Q4 2021 Feb 14, 2022	BUY	$8.86 - $13.47 $9,861 - $14,992	1,113 Added 13912.5%	1,121 $12,000
Q1 2021 May 12, 2021	SELL	$14.61 - $22.19 $4,251 - $6,457	-291 Reduced 97.32%	8 $0
Q4 2020 Feb 11, 2021	BUY	$14.28 - $25.06 $4,269 - $7,492	299 New	299 $6,000

Others Institutions Holding LRMR

# of Institutions

127

Shares Held

67.3M

Call Options Held

280K

Put Options Held

76.3K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $164M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account